<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03729765</url>
  </required_header>
  <id_info>
    <org_study_id>2018035X</org_study_id>
    <nct_id>NCT03729765</nct_id>
  </id_info>
  <brief_title>Hemoperfusion in Extracorporeal Membrane Oxygenation (ECMO) Patients</brief_title>
  <official_title>A Randomized, Controlled Trial: Hemoperfusion in Extracorporeal Membrane Oxygenation (ECMO) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Anzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Anzhen Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Extracorporeal membrane oxygenation (ECMO) is a temporary mechanical circulatory support
      device for cardiogenic shock (CS) patients. During extracorporeal membrane oxygenation (ECMO)
      support, the inflammatory response is intense and complex. It may cause infection, cell
      damage, organ dysfunction and even death. Hemoperfusion can adsorb inflammatory factors and
      reduce the inflammatory reaction. CS patients who are likely to receive veno-arterial
      extracorporeal membrane oxygenation (VA-ECMO) support will be enrolled and randomized with a
      1:1 allocation to a simultaneous hemoperfusion arm vs. standard care arm.

        1. The patients in the simultaneous hemoperfusion arm will receive hemoperfusion when
           extracorporeal membrane oxygenation (ECMO) is commenced.

        2. The patients in the standard care arm will not receive hemoperfusion when extracorporeal
           membrane oxygenation (ECMO) is commenced.

      The primary outcome is the change of plasma interleukin (IL)-6 level after hemoperfusion is
      commenced.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 19, 2018</start_date>
  <completion_date type="Anticipated">July 5, 2021</completion_date>
  <primary_completion_date type="Anticipated">November 5, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change of plasma interleukin (IL)-6 level</measure>
    <time_frame>3 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>change of other inflammatory factor level</measure>
    <time_frame>3 days</time_frame>
    <description>plasma interleukin (IL)-1β、8、10（pg/ml）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of other inflammatory factor level</measure>
    <time_frame>3 days</time_frame>
    <description>tumor necrosis factor α (TNF-α)（fmol/ml）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>change of other inflammatory factor level</measure>
    <time_frame>3 days</time_frame>
    <description>C-reactive protein (CRP)（mg/dl）</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of Multiple organ dysfunction syndrome (MODS)</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of infection</measure>
    <time_frame>30 days</time_frame>
    <description>Any kinds of infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration on extracorporeal membrane oxygenation (ECMO) support</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of successful weaning from extracorporeal membrane oxygenation (ECMO)</measure>
    <time_frame>30 days</time_frame>
    <description>The circulation doesn't deteriorate in 24 hours since weaning from ECMO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration on invasive ventilation</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>60 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of adverse event</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cardiogenic Shock</condition>
  <arm_group>
    <arm_group_label>hemoperfusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients in the simultaneous hemoperfusion arm will receive hemoperfusion when extracorporeal membrane oxygenation (ECMO) is commenced. veno-arterial extracorporeal membrane oxygenation (VA-ECMO) patients treat with hemoperfusion three times in a row，each time for 6 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The patients in the standard care arm will not receive hemoperfusion when lextracorporeal membrane oxygenation (ECMO) is commenced.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>hemoperfusion</intervention_name>
    <description>The patients in the simultaneous hemoperfusion arm will receive hemoperfusion when extracorporeal membrane oxygenation (ECMO) is commenced. veno-arterial extracorporeal membrane oxygenation (VA-ECMO) patients treat with hemoperfusion three times in a row，each time for 6 hours.</description>
    <arm_group_label>hemoperfusion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 and ≤ 75 years.

          2. Admission to ICU.

          3. Criteria for the diagnosis of CS as follows: (1) systolic blood pressure less than 90
             mmHg for 30 min, a mean arterial pressure less than 65 mmHg for 30 min, or
             vasopressors required to achieve a blood pressure ≥ 90 mmHg; (2) pulmonary congestion
             or elevated left-ventricular filling pressures; and (3) signs of impaired organ
             perfusion with at least one of the following criteria: (a) altered mental status; (b)
             cold, clammy skin; (c) oliguria; and (d) increased serum lactate.

          4. ECMO will supply cardiopulmonary support to the patient

          5. The patients will be enrolled and randomized when ECMO is commenced less than 24
             hours.

        Exclusion Criteria:

          1. Refusal of consent.

          2. Active hemorrhage or thrombocytopenic purpura

          3. BMI≥40

          4. Received ECMO bridging to a long-term ventricle assist device or heart
             transplantation.

          5. Infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Xiaotong Hou, PhD., Md.</last_name>
    <phone>86 18911662932</phone>
    <email>xt.hou@ccmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Center for Cardiac Intensive Care, Beijing Anzhen Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaotong Hou, PhD., MD.</last_name>
      <phone>86 18911662932</phone>
      <email>xt.hou@ccmu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Xiaotong Hou, PhD., MD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>October 30, 2018</study_first_submitted>
  <study_first_submitted_qc>November 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 5, 2018</study_first_posted>
  <last_update_submitted>January 25, 2019</last_update_submitted>
  <last_update_submitted_qc>January 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Anzhen Hospital</investigator_affiliation>
    <investigator_full_name>Xiaotong Hou</investigator_full_name>
    <investigator_title>Director of Center for Cardiac Intensive Care</investigator_title>
  </responsible_party>
  <keyword>veno-arterial extracorporeal membrane oxygenation (VA-ECMO)</keyword>
  <keyword>hemoperfusion</keyword>
  <keyword>inflammatory factor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Cardiogenic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

